DDInter1845 DDInter1376
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phentermine
Tranylcypromine {u} (Compound) resembles {v} (Compound) Dextroamphetamine
Tranylcypromine {u} (Compound) binds {v} (Gene) CYP2C19
Tranylcypromine {u} (Compound) upregulates {v} (Gene) SLC35F2
Tranylcypromine {u} (Compound) downregulates {v} (Gene) TCEB2
Tranylcypromine {u} (Compound) causes {v} (Side Effect) Oedema
Tranylcypromine (Compound) resembles Phentermine (Compound)
Tranylcypromine (Compound) resembles Dextroamphetamine (Compound)
Tranylcypromine (Compound) binds CYP2C19 (Gene)
Tranylcypromine (Compound) upregulates SLC35F2 (Gene)
Tranylcypromine (Compound) downregulates TCEB2 (Gene)
Tranylcypromine (Compound) causes Oedema (Side Effect)